Observational study associates circulating tumor DNA with enhanced prognostic impact and survival rates in Hodgkin lymphoma patients.
Key Points
To evaluate the utility of circulating tumor DNA in determining minimal residual disease and its correlation with patient outcomes in Hodgkin lymphoma.
Analyzed patients diagnosed with Hodgkin lymphoma using circulating tumor DNA techniques.
Assessed minimal residual disease after treatment using next generation sequencing.
Compared results of ctDNA analysis with PET/CT evaluations and examined prognostic implications.
At diagnosis, ctDNA identified tumor-specific mutations in 69% of patients.
Patients with negative ctDNA had a 3-year progression-free survival rate of 88% vs. 25% for positive cases.
Combining PET/CT and ctDNA yielded three distinct prognostic groups with varying survival outcomes.
Cite This Study
García‐Bacelar et al. (2025) studied this question.